Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAnemia, SideroblasticBone MarrowAzacitidineMyelodysplastic-Myeloproliferative DiseasesMyeloproliferative DisordersPreleukemiaTreatment OutcomeChromosome AberrationsKaryotypingMonosomyThalidomidePrognosisAnemia, AplasticAcute DiseaseCytogenetic AnalysisLeukemiaChromosomes, Human, Pair 7PancytopeniaBone Marrow CellsRetrospective StudiesHematopoietic Stem Cell TransplantationGranulocyte Precursor CellsChromosome DeletionSurvival AnalysisNeoplasms, Second PrimaryRemission InductionBone Marrow DiseasesTransplantation, HomologousIron OverloadCytogeneticsAntimetabolites, AntineoplasticCytarabineErythrocyte TransfusionSurvival RateBlood TransfusionChelation TherapyTrisomyHematopoietic Stem CellsAntigens, CD34Hematologic AgentsTransplantation ConditioningErythropoietinHematologic NeoplasmsProspective StudiesBlast CrisisBone Marrow ExaminationAntineoplastic AgentsBlood Cell CountHematologic DiseasesVidarabineDisease ProgressionThrombocytopeniaRisk FactorsHematopoiesisFollow-Up StudiesRecurrenceGranulocyte Colony-Stimulating FactorAnemiaLeukemia, Myelomonocytic, AcuteBone Marrow TransplantationThrombocytosisIsochromosomesAnemia, MacrocyticIn Situ Hybridization, FluorescenceAntineoplastic Combined Chemotherapy ProtocolsCore Binding Factor Alpha 2 SubunitTranslocation, GeneticTime FactorsMutationDisease-Free SurvivalPrecursor Cell Lymphoblastic Leukemia-LymphomaChromosomes, Human, Pair 8HematinicsErythroid Precursor CellsPrimary MyelofibrosisChromosomes, Human, Pair 20IdarubicinDrug Administration ScheduleArabinonucleosidesImmunophenotypingIron Chelating AgentsFlow CytometryAntilymphocyte SerumBusulfanCohort StudiesKaryotypeLeukemia, Myelogenous, Chronic, BCR-ABL PositiveErythroid CellsHaploinsufficiencyErythroblastsChromosome DisordersAge FactorsGraft vs Host Disease